Previous and ongoing clinical trials targeting tumor-associated glycans or lectins
| Target | Drug candidate | Modality | Phase | Cancer type | Citation/Trial ID |
| NeuGcGM3 | Racotumomab | Vaccine | II/III | NSCLC | (66 67), NCT01460472 |
| Lewis-Y antigen | hu3S193 | mAb | I/II | Advanced epithelial cancer; platinum resistant/refractory ovarian, Fallopian tube and primary peritoneal carcinoma | (70 71) |
| MUC1 | PankoMab-GEX (Gatipotuzumab) | mAb | I/II | Advanced carcinoma; recurrent ovarian carcinoma | (74 75) |
| Lewis-Y antigen | SGN-15 | ADC | II | NSCLC | (79) |
| Lewis-Y antigen | BMS-1 82 248–1 | ADC | II | Metastatic breast cancer | (80) |
| CD22/CD19 | DT2219 | BsAb | I | Refractory B-cell malignancies | (89) |
| TAG72 | CART72 | CAR T | I | Advanced colorectal cancer | (96) |
| Lewis-Y antigen | Ley-CAR T | CAR T | I | AML | (102) |
| Lewis-Y antigen | Ley-CAR T | CAR T | I | Advanced solid tumors | NCT03851146 |
| GD2 | GD2-iCAR-PBT | CAR T | I | Metastatic melanoma | (105) |
| GD2 | GD2-CAR3 combined with lymphodepletion and PD-1 blockade | CAR T | I | Relapsed or refractory neuroblastoma | (106) |
| IL15-GD2 | GINAKIT | CAR-NKT | I | Pediatric neuroblastoma | NCT03294954 |
| STn | Theratope | ADC | III | Metastatic breast adenocarcinoma | (115 116) |
| Siglec-15 | NC318 | mAb | I/II | Advanced or metastatic solid tumors | NCT03665285 |
ADC, antibody-drug conjugates; AML, acute myeloid leukemia; mAb, monoclonal antibody; MUC1, mucin 1; NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1.